- Home
- GOAI vs XOMAO Comparison
GOAI vs XOMAO Comparison
Compare GOAI & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$3.96
N/A
Current Price
$25.85
Company Overview
Basic Information| Metric | GOAI | XOMAO |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GOAI | XOMAO |
|---|---|---|
| Price | $3.96 | $25.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 566.3K | 2.9K |
| Earning Date | 04-10-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $24.74 |
| 52 Week High | $6.67 | $26.40 |
Technical Indicators
Market Signals| Indicator | GOAI | XOMAO |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 54.64 |
| Support Level | $3.48 | $25.16 |
| Resistance Level | $4.40 | $26.40 |
| Average True Range (ATR) | 0.39 | 0.22 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 54.42 | 50.00 |
Price Performance
Historical Comparison GOAI
XOMAO
About GOAI Eva Live Inc. Common Stock
EVA LIVE INC
About XOMAO AGNC Investment Corp.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.